Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis

Abstract

These data suggest colchicine, in addition to guideline-directed medical therapy following acute coronary syndrome reduces MACE, cerebrovascular accidents, and rates of urgent revascularization at 2 years of follow-up.